Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists

Sean Ekins, Vladyslav Kholodovych, Ni Ai, Michael Sinz, Joseph Gal, Lajos Gera, William J. Welsh, Kenneth Bachmann and Sridhar Mani
Molecular Pharmacology September 2008, 74 (3) 662-672; DOI: https://doi.org/10.1124/mol.108.049437
Sean Ekins
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladyslav Kholodovych
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ni Ai
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Sinz
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Gal
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lajos Gera
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Welsh
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Bachmann
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sridhar Mani
Collaborations in Chemistry, Jenkintown, Pennsylvania (S.E.); Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland (S.E.); Department of Pharmacology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey (S.E., V.K., N.A., W.J.W.); Bristol-Myers Squibb Company, Wallingford, Connecticut (M.S.); Division of Clinical Pharmacology (J.G.) and Biochemistry and Molecular Genetics (L.G.), University of Colorado Denver, School of Medicine, Aurora, Colorado; Department of Pharmacology, The University of Toledo College of Pharmacy, Toledo, Ohio (K.B.); and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York (S.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3′,5-dimethyl-3,5′-biisoxazole-4′-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)-4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 74 (3)
Molecular Pharmacology
Vol. 74, Issue 3
1 Sep 2008
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists

Sean Ekins, Vladyslav Kholodovych, Ni Ai, Michael Sinz, Joseph Gal, Lajos Gera, William J. Welsh, Kenneth Bachmann and Sridhar Mani
Molecular Pharmacology September 1, 2008, 74 (3) 662-672; DOI: https://doi.org/10.1124/mol.108.049437

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Computational Discovery of Novel Low Micromolar Human Pregnane X Receptor Antagonists

Sean Ekins, Vladyslav Kholodovych, Ni Ai, Michael Sinz, Joseph Gal, Lajos Gera, William J. Welsh, Kenneth Bachmann and Sridhar Mani
Molecular Pharmacology September 1, 2008, 74 (3) 662-672; DOI: https://doi.org/10.1124/mol.108.049437
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics